Ipamorelin vs GHRP-2
Compare receptor pharmacology, GH response, appetite effects and evidence maturity rather than declaring a winner.
| Attribute | Ipamorelin | GHRP-2 |
|---|---|---|
| Human evidence | Human evidence includes early PK/GH-response studies and a randomized Phase II postoperative-ileus trial. In that trial, IV ipamorelin 0.03 mg/kg twice daily did not significantly improve the primary or key secondary efficacy endpoints versus placebo. | Small human physiology studies show GH release, increased food intake and activation of ACTH/prolactin pathways. |
| Research focus | GH-axis physiology and motility research | GH-axis physiology |
| Regulatory status | Not FDA-approved; FDA lists safety concerns for compounded ipamorelin. | Not FDA-approved; FDA highlights compounding safety uncertainty. |
| Route / formulation | The Phase II evidence was intravenous in postoperative patients and cannot be transferred to subcutaneous wellness/bodybuilding use. | Acute hormone release does not prove body-composition or performance benefit. |
Why these are compared
These compounds appear in the gh secretagogue comparison evidence landscape, but they are not interchangeable. Ipamorelin is ghrelin-receptor/gh secretagogue peptide studied in gh-axis physiology and motility research; GHRP-2 is growth-hormone secretagogue hexapeptide studied in gh-axis physiology. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
Ipamorelin: Human Phase I/II exposure; tested Phase II indication was negative; no lifestyle efficacy established.
GHRP-2: Limited human physiology / endocrine evidence; lifestyle efficacy unproven.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No head-to-head clinical outcome trial identified. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.